THIRD GENERATION SEQUENCING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Third Generation Sequencing Market Analysis & Forecast: 2026-2033

Third Generation Sequencing Market is estimated to be valued at USD 1,069.1 Mn in 2026 and is expected to reach USD 4,131.0 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 21.3% from 2026 to 2033.

Key Takeaways

• By Type of Technology, Single Molecule Real Time (SMRT) sequencing division dominates the third-generation sequencing (TGS) market by holding 45.7% of the market share in 2026.
• By Region, North America leads the global TGS market by holding 36.9% share during the forecast period.

Market Overview

The global third generation sequencing (TGS) market is witnessing accelerated growth, fueled by the increasing demand for high-throughput, accurate, and real-time genomic analysis. Unlike earlier sequencing technologies, TGS enables long-read sequencing, facilitating improved detection of complex genetic variations and structural anomalies. This has led to its rising adoption across diverse applications, including human genomics, oncology, microbiology, and agriculture.

Current Events and its Impact on the Third Generation Sequencing Market

Third Generation Sequencing Market Trends

• Technology Advancements

TGS technologies are continuously evolving, with ongoing advancements in sequencing chemistry, instrument performance, and data analysis tools. These advancements aim to improve accuracy, read lengths, sequencing speed, and cost-effectiveness of TGS platforms. Trends include the development of novel sequencing chemistries, miniaturization of sequencing devices, and improved base-calling algorithms. In April 2025, a team of researchers introduced a memristor-based hardware-software co-design that processes raw sequencer signals directly in analog memory. This innovation enables real-time genomic analysis, achieving a 97.15% F1 score in virus raw signal mapping, with a 51x speed increase and 477x energy savings compared to traditional methods.

• Increasing Adoption of TGS Platforms

The adoption of TGS platforms has been steadily increasing across various industries and research fields. Researchers and healthcare professionals are recognizing the benefits of long-read sequencing and real-time sequencing capabilities offered by TGS technologies. As the technologies become more established and accessible, their adoption is expected to continue to grow.

In May 2025, Oxford Nanopore Technologies, a UK biotech company specializing in gene sequencing, became a takeover target as its shares fell 85%. CEO Gordon Sanghera acknowledged the company's vulnerability to acquisition after his veto rights expired. High-profile diagnostics companies such as Thermo Fisher Scientific or Danaher have shown interest.

Opportunities in the Third Generation Sequencing Market

• Genomics Research

TGS technologies provide researchers with the ability to generate long-read sequences and capture complex genomic information. This opens up new opportunities for advancing genomics research, including the discovery of novel genetic variations, understanding gene regulation mechanisms, and studying the structure and function of genomes in greater detail.

For instance, on August 2023, PacBio, a leading provider of high-quality, highly accurate sequencing solutions, and GeneDx, a leader in improving health outcomes through genomic and clinical insights, have announced a research collaboration with the University of Washington to investigate the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

Clinical Diagnostics

TGS platforms offer potential applications in clinical diagnostics, especially in the identification and characterization of genetic variants associated with diseases. TGS can provide more comprehensive and accurate genetic information, enabling improved diagnosis, personalized treatment strategies, and monitoring of treatment response.

For instance, on April 14, 2023, Oxford Nanopore Technologies plc, company that provides a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in in vitro diagnostics, announced a collaboration to improve global health outcomes by exploring specific opportunities to bring nanopore sequencing to the infectious disease diagnostics market. The companies are working together to identify and pursue opportunities to improve patient care through access to nanopore-based clinical research and in vitro diagnostic (IVD) solutions.

Segmental Insights

Third Generation Sequencing Market Insights, By Type of Technology

Single Molecule Real-Time (SMRT) sequencing holds the largest market share due to its long-read capability and high accuracy, essential for complex genome assemblies and structural variation analysis. Nanopore sequencing is rapidly gaining traction thanks to its portability, real-time data output, and affordability, making it ideal for field diagnostics and rapid testing. Other emerging platforms, such as synthetic long-read technologies, complement these methods by enhancing resolution and data quality.

Continuous improvements in sequencing chemistry, read length, and error correction software are driving technology adoption across clinical, research, and industrial applications, expanding the market’s scope and geographic reach.

Third Generation Sequencing Market Insights, By End User

Hospitals and clinics are increasingly utilized TGS technologies for accurate pathogen detection and personalized treatment plans. Academic and biotech research institutions are also major users, applying TGS for genome assembly, epigenetics, and evolutionary biology. Public health agencies leverage these platforms for pathogen surveillance and outbreak management.

Additionally, pharmaceutical companies incorporate TGS in drug discovery and biomarker identification. This broad spectrum of applications across healthcare, research, and public health sectors underpins sustained market expansion and innovation.

Regional Insights

North America Third Generation Sequencing Market Trends and Analysis

North America is expected to lead the global third generation sequencing market, with the U.S. at the forefront. Growing awareness of genomics in healthcare, rising investments in precision medicine, and strong government funding for pathogen genomics accelerate demand. The extensive adoption of sequencing technologies across clinical diagnostics, research, and infectious disease monitoring drives market expansion.

Europe Third Generation Sequencing Market Trends and Analysis

Europe is projected to hold the second-largest share in the third-generation sequencing market. Countries like Germany, the UK, and France are key contributors, driven by increasing investments in genomics research and robust healthcare infrastructure. Strict regulatory frameworks promoting data quality and patient safety encourage sequencing adoption. Growing public health initiatives, especially in cancer and infectious disease research, support market growth. 

Third Generation Sequencing Market Dominating Countries:

United States and Canada

The United States and Canada lead the global third generation sequencing market, holding significant market shares in North America. The U.S. drives growth with strong government funding, advanced genomics research facilities, and widespread use in clinical diagnostics and infectious disease monitoring. Canada supports the market with robust biotech initiatives and increasing adoption of precision medicine technologies. Both countries benefit from well-established healthcare infrastructure, stringent regulatory frameworks, and collaborations between academia and industry.

Market Report Scope

Analyst Viewpoint – Third Generation Sequencing Market

• The third generation sequencing market is witnessing strong growth driven by the rising demand for rapid and accurate genomic analysis across clinical diagnostics, infectious disease surveillance, and personalized medicine. Analysts emphasize that the need for real-time sequencing, especially in pathogen detection and cancer genomics, is accelerating the adoption of third generation technologies due to their ability to deliver long-read sequences with higher accuracy and faster turnaround times.
• Technological innovations, including nanopore sequencing and single-molecule real-time (SMRT) sequencing, are enhancing data quality, throughput, and application versatility. Integration with bioinformatics platforms and cloud-based data analysis tools is improving accessibility for both research institutions and clinical labs. These advancements are enabling expanded use in areas like rare disease research, agriculture genomics, and microbiome studies.
• Geographically, North America leads the market, supported by substantial government funding and well-established genomics infrastructure. Asia Pacific is the fastest-growing region, fueled by increasing healthcare investments and rising awareness in China and India. Europe remains a key market due to stringent regulatory standards and innovation in precision medicine.
• Experts advise companies to focus on continuous innovation, data integration capabilities, and collaborative partnerships to capitalize on evolving market opportunities. As genomic sequencing becomes integral to healthcare and biotech research, demand for efficient, scalable, and cost-effective third generation sequencing platforms is expected to grow steadily.

Third Generation Sequencing Market: Key Development

• In March 2025, Pacific Biosciences launched its latest SMRT sequencing platform, featuring enhanced accuracy and longer read lengths to accelerate genomic research and clinical diagnostics. The system targets academic institutions and biotech companies focusing on complex genome assemblies and epigenetic studies, strengthening PacBio’s position in high-precision sequencing technologies.
• In February 2025, Oxford Nanopore Technologies expanded its product line by introducing a portable nanopore sequencer with real-time data streaming and cloud analytics. Designed for field-based applications such as infectious disease monitoring and environmental genomics, this innovation supports rapid decision-making in remote and resource-limited settings.
• In January 2025, Illumina announced a strategic collaboration with a leading cancer research institute to develop third generation sequencing solutions for liquid biopsy applications. This partnership aims to enhance early cancer detection and personalized treatment strategies through improved long-read sequencing accuracy.
• In December 2024, Roche unveiled a new third generation sequencing workflow integrating sample preparation, sequencing, and AI-driven data analysis. The streamlined platform addresses growing demand for turnkey solutions in clinical genomics and precision medicine.

Market Segmentation

• By Technology (Revenue, USD Mn, 2021 - 2033)
  • Single-Molecule Real-Time (SMRT) Sequencing
  • Nanopore Sequencing
  • Synthetic long-read sequencing
• By Component (Revenue, USD Mn, 2021 - 2033)
  • Products
  • Services
• By (Revenue, USD Mn, 2021 - 2033) Application
  • Genome Sequencing
  • Epigenetics
  • Transcriptomics
  • Metagenomics
  • Others
• By End-user (Revenue, USD Mn, 2021 - 2033)
  • Biopharmaceutical companies
  • Hospitals and clinics
  • Contract research organizations (CROs)
  • Others (Academic and research institutes)
• By Geography (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Company Profiles
  • PacBio
  • Oxford Nanopore Technologies, Ltd.
  • BGI Genomics Co., Ltd.
  • F.Hoffmann-La Roche AG
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • GenapSys Inc.
  • Loop Genomics
  • Nabsys, Inc.
  • Genia Technologies, Inc.
  • Stratos Genomics, Inc.
  • GATC Biotech AG
  • Phase Genomics, Inc.

Sources

The Stakeholders Consulted

• Genomics researchers and molecular biologists
• Manufacturers and suppliers of sequencing platforms and consumables
• Clinical diagnostics and healthcare professionals
• Biotechnology and pharmaceutical companies
• Bioinformatics and data analytics experts
• Regulatory authorities and compliance consultants
• Academic institutions and research organizations focused on genomics and precision medicine

Databases Opened

• National Center for Biotechnology Information (NCBI) – Genomic Databases
• European Bioinformatics Institute (EBI) – Sequencing Data Archives
• U.S. Food and Drug Administration (FDA) – Medical Device and Diagnostic Reports
• World Health Organization (WHO) – Genomic Surveillance Data

Magazines & Trade Publications

• Nature Biotechnology
• Genetic Engineering & Biotechnology News
• BioTechniques
• GenomeWeb
• The Scientist – Genomics Section

Scientific and Industry Journals

• Genome Research
• Nature Genetics
• PLOS Genetics
• Journal of Clinical Genomics
• Trends in Biotechnology

Newspapers & Media Outlets

• The New York Times – Health & Science
• Reuters – Biotechnology News
• Financial Times – Healthcare & Life Sciences
• The Guardian – Science & Technology

Associations and Regulatory Bodies

• National Institutes of Health (NIH)
• International Society for Computational Biology (ISCB)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Global Alliance for Genomics and Health (GA4GH)

Public Domain Sources

• National Human Genome Research Institute (NHGRI) – Genomic Research Reports
• World Health Organization (WHO) – Global Genomic Surveillance
• United Nations – Health and Biotechnology Reports
• OECD – Biotechnology and Innovation Data

Proprietary Research Elements

• Internal Market Analytics Platform
• Expert Interviews and Panel Discussions with Genomics Industry Leaders
• Customized Data Modelling and Forecasting Tools
• Survey Data from Healthcare Providers and Research Institutions